Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.
Fineman MS, McAlindon TE, Lattermann C, Swearingen CJ, Kennedy S, Lopez VA, Simsek I, Tambiah JRS, Yazici Y. Fineman MS, et al. Among authors: swearingen cj. Rheumatol Ther. 2023 Dec;10(6):1741-1752. doi: 10.1007/s40744-023-00604-7. Epub 2023 Oct 30. Rheumatol Ther. 2023. PMID: 37902943 Free PMC article.
Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study.
Yazici Y, Tambiah JRS, Swearingen CJ, Britt J, Kennedy S, Fineman MS, Simsek I, Solomon E, McAlindon TE. Yazici Y, et al. Among authors: swearingen cj. Clin Exp Rheumatol. 2025 Jan 13. doi: 10.55563/clinexprheumatol/hjt118. Online ahead of print. Clin Exp Rheumatol. 2025. PMID: 39808286
A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients.
Yazici Y, Tambiah JRS, Swearingen CJ, Lopez VA, Kennedy S, Fineman MS, Simsek I, Solomon E, Mcalindon TE. Yazici Y, et al. Among authors: swearingen cj. Clin Exp Rheumatol. 2025 Jan 13. doi: 10.55563/clinexprheumatol/gskbin. Online ahead of print. Clin Exp Rheumatol. 2025. PMID: 39808288
Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden.
Dowell S, Swearingen CJ, Pedra-Nobre M, Wollaston D, Najmey S, Elliott CL, Ford TL, North H, Dore R, Dolatabadi S, Ramanujam T, Kennedy S, Ott S, Jileaeva I, Richardson A, Wright G, Kerr GS. Dowell S, et al. Among authors: swearingen cj. ACR Open Rheumatol. 2023 Aug;5(8):381-387. doi: 10.1002/acr2.11575. Epub 2023 Jun 19. ACR Open Rheumatol. 2023. PMID: 37334885 Free PMC article.
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. Yazici Y, et al. Among authors: swearingen cj. Osteoarthritis Cartilage. 2021 May;29(5):654-666. doi: 10.1016/j.joca.2021.02.004. Epub 2021 Feb 12. Osteoarthritis Cartilage. 2021. PMID: 33588087 Free article. Clinical Trial.
71 results